Document Detail

A phase II study of bortezomib in patients with MALT lymphoma.
MedLine Citation:
PMID:  19336742     Owner:  NLM     Status:  MEDLINE    
We have performed a phase II study to evaluate bortezomib in patients with MALT-lymphoma. Sixteen patients entered the trial, 4 had gastric MALT-lymphoma, 7 of the ocular adnexa, one of the colon, and 2 of the parotid, and one patient each the lung and the breast. Bortezomib was given at 1.5 mg/m(2) days 1, 4, 8 and 11; repeated every 21 days. The overall response rate was 80% (13/16); 7 patients achieved complete remission (43%), 6 partial response (37%) and 3 stable disease. After a median follow-up of 23 months (range; 8-26), all patients are alive and 4 have relapsed. Fifteen patients required dose reductions due to either neuropathy (7 patients) or diarrhea (8 patients). Bortezomib appears to be active in patients with MALT-lymphoma. However, an unexpectedly high rate of toxicities was seen, warranting assessment of combination schedules with bortezomib at a lower dose than given in our study.
Marlene Troch; Constanze Jonak; Leonhard Müllauer; Andreas Püspök; Michael Formanek; Wolfgang Hauff; Christoph C Zielinski; Andreas Chott; Markus Raderer
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article     Date:  2009-03-31
Journal Detail:
Title:  Haematologica     Volume:  94     ISSN:  1592-8721     ISO Abbreviation:  Haematologica     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-05-01     Completed Date:  2009-09-25     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  738-42     Citation Subset:  IM    
Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Waehringer Guertel 18-20, Vienna, Austria.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage,  adverse effects,  therapeutic use
Boronic Acids / administration & dosage,  adverse effects,  therapeutic use*
Diarrhea / chemically induced
Follow-Up Studies
Lymphoma, B-Cell, Marginal Zone / drug therapy*,  pathology
Middle Aged
Nausea / chemically induced
Nervous System Diseases / chemically induced
Pyrazines / administration & dosage,  adverse effects,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents; 0/Boronic Acids; 0/Pyrazines; 0/bortezomib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Storage and regulated secretion of factor VIII in blood outgrowth endothelial cells.
Next Document:  Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-syst...